SCHEMBL13197822

SCHEMBL13197822

CC(CO)NC(=O)c1nc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cn1CCOc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 5/20 0.43
KCNA5 P22460 1/20 0.43
IGF1R P08069 2/20 0.41
FPR2 P25090 1/20 0.41
AHR P35869 1/20 0.41
PPARA Q07869 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
P2RY1 P47900 2/20 0.40
P2RY2 P41231 1/20 0.40
P2RY14 Q15391 1/20 0.40
RAF1 P04049 1/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
IDH1 O75874 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13197837 0.88 SMN1; SMN2 (0.48) EPHX2IGF1RFPR2AHRPPARA
SCHEMBL13197853 0.87 EPHX2 (0.43) EPHX2AHRRAF1ALDH1A1HPGD
SCHEMBL2881513 0.86 EPHX2 (0.49) EPHX2KCNA5IGF1RFPR2PPARA
SCHEMBL13197820 0.86 EPHX2 (0.46) EPHX2KCNA5IGF1RPPARACYP1A2
SCHEMBL13197880 0.83 EPHX2 (0.43) EPHX2KCNA5IGF1RPPARACYP1A2
SCHEMBL13197817 0.83 EPHX2 (0.44) EPHX2AHRALDH1A1HPGD
SCHEMBL13197846 0.83 EPHX2 (0.42) EPHX2IGF1RFPR2AHRRAF1
SCHEMBL13197819 0.83 PPARA (0.46) EPHX2IGF1RPPARA
SCHEMBL13197831 0.82 EPHX2 (0.42) EPHX2IGF1RFPR2AHRRAF1
SCHEMBL13197884 0.82 MCHR1 (0.43) EPHX2KCNA5IGF1RCYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds IRF3, EIF2AK2, ZC3HAV1 EPHX2 3922/4885KCNA5 4149/4885IGF1R 400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.